Monopar Therapeutics Inc. (MNPR) Bundle
A Brief History of Monopar Therapeutics Inc.
Company Overview
Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer and rare diseases. The company has a robust pipeline, including investigational drug candidates such as ALXN-1840 for Wilson disease and several radiopharmaceutical programs.
Financial Performance
As of September 30, 2024, Monopar reported a net loss of $4.66 million for the nine-month period, compared to a net loss of $6.59 million for the same period in 2023. The decrease in net loss is attributed to reduced operating expenses, particularly in research and development.
| Financial Metrics | 2024 (Nine Months Ended Sept 30) | 2023 (Nine Months Ended Sept 30) | Variance |
|---|---|---|---|
| Net Loss | $4.66 million | $6.59 million | $1.93 million |
| Research and Development Expenses | $3.08 million | $4.56 million | $1.48 million |
| General and Administrative Expenses | $2.01 million | $2.35 million | $0.34 million |
Cash Flow Analysis
For the nine months ended September 30, 2024, Monopar reported net cash used in operating activities of $4.41 million, a decrease from $6.31 million in 2023. The company raised $3.15 million through financing activities compared to $1.69 million in the previous year.
| Cash Flow Metrics | 2024 (Nine Months Ended Sept 30) | 2023 (Nine Months Ended Sept 30) | Variance |
|---|---|---|---|
| Net Cash Used in Operating Activities | $(4.41) million | $(6.31) million | $1.90 million |
| Net Cash Provided by Financing Activities | $3.15 million | $1.69 million | $1.46 million |
Stock Performance
As of October 31, 2024, Monopar's stock price averaged $7.73 per share, with a substantial increase in shares sold under the Capital on Demand™ Sales Agreement with JonesTrading. The company sold 557,761 shares, yielding net proceeds of approximately $4.20 million.
Capital Structure
As of September 30, 2024, Monopar had total stockholders' equity of approximately $4.95 million, down from $5.59 million at the beginning of the year. The company has experienced a cumulative deficit of about $64.87 million as of September 30, 2024.
| Equity Metrics | As of Sept 30, 2024 | As of Jan 1, 2024 |
|---|---|---|
| Total Stockholders' Equity | $4.95 million | $5.59 million |
| Cumulative Deficit | $(64.87) million | $(60.21) million |
Research and Development Focus
Monopar continues to invest heavily in R&D, with a focus on advancing its clinical trials for radiopharmaceuticals and other therapeutic candidates. As of September 30, 2024, R&D expenses totaled $3.08 million, reflecting ongoing efforts in these areas.
Future Outlook
Looking ahead, Monopar anticipates seeking additional capital to support its ongoing clinical trials and product development initiatives. The company expects its current funds to last at least into the first half of 2026, which will help sustain its operational and strategic objectives.
A Who Owns Monopar Therapeutics Inc. (MNPR)
Shareholder Composition
As of September 30, 2024, Monopar Therapeutics Inc. had a total of 3,525,079 shares of common stock issued and outstanding following a 1-for-5 reverse stock split effective August 12, 2024. The company’s significant shareholders include:
| Shareholder | Ownership Percentage | Number of Shares Owned |
|---|---|---|
| Tactic Pharma, LLC | 24.3% | 856,520 |
| Other Institutional Investors | Approximately 30% | 1,057,524 |
| Public Float | 45.7% | 1,611,035 |
Financial Overview
For the nine months ended September 30, 2024, Monopar reported a net loss of $4,660,811, with total operating expenses of $5,087,077. The company’s total stockholders’ equity as of September 30, 2024, was $4,946,787.
Recent Stock Performance
During the nine months ended September 30, 2024, Monopar sold 509,061 shares of common stock at an average gross price of $6.45 per share, resulting in net proceeds of $3,194,310 after fees and commissions of $81,932. The stock price has fluctuated, reflecting investor sentiment and corporate developments.
Executive Ownership
The company's executive officers hold a minority stake, with the following key figures:
| Name | Position | Shares Owned |
|---|---|---|
| Chandler D. Robinson | CEO, Co-Founder | 135,000 |
| Michael Brown | Board Member | 100,000 |
Future Equity Financing
Monopar has a Capital on Demand Sales Agreement with JonesTrading Institutional Services, which allows the company to sell shares up to a total of $6,505,642. As of September 30, 2024, $5,446,975 had been sold under this agreement.
Monopar Therapeutics Inc. (MNPR) Mission Statement
Company Overview
Monopar Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of innovative therapies for cancer and rare diseases. The company is dedicated to addressing unmet medical needs through its proprietary drug candidates, particularly in the field of radiopharmaceuticals and other therapeutic areas.
Mission Statement
Monopar Therapeutics aims to leverage its advanced scientific platform to deliver novel and effective treatments for patients suffering from serious and life-threatening conditions. The company is committed to maintaining the highest standards of integrity, transparency, and collaboration in its efforts to enhance the quality of life for patients and their families.
Strategic Goals
- Innovation: To develop cutting-edge therapies that utilize novel mechanisms of action.
- Collaboration: To partner with leading organizations and institutions to accelerate drug development.
- Patient-Centric Approach: To prioritize patient needs and outcomes in all aspects of development.
- Regulatory Excellence: To achieve timely regulatory approvals through rigorous clinical trial design and execution.
Financial Performance Overview
As of September 30, 2024, Monopar Therapeutics reported a net loss of $4,660,811 for the nine months ending on that date, compared to a net loss of $6,588,281 for the same period in 2023. The company’s total operating expenses for the nine months ended September 30, 2024, were $5,087,077.
| Financial Metrics | 2024 (9 Months) | 2023 (9 Months) |
|---|---|---|
| Net Loss | $4,660,811 | $6,588,281 |
| Total Operating Expenses | $5,087,077 | $6,919,247 |
| Research and Development Expenses | $3,081,366 | $4,564,602 |
| General and Administrative Expenses | $2,005,711 | $2,354,645 |
| Weighted Average Shares Outstanding | 3,419,321 | 2,710,356 |
Research and Development Focus
Monopar's current pipeline includes several key investigational products:
- ALXN-1840: An investigational drug for Wilson disease.
- MNPR-101-Zr: A radiopharmaceutical imaging agent for advanced cancers currently in Phase 1.
- MNPR-101-Lu: A therapeutic radiopharmaceutical for advanced cancers in Phase 1a.
- MNPR-101-Ac225: A late preclinical-stage development for advanced cancers.
Recent Developments
As of October 31, 2024, Monopar Therapeutics has 5,277,796 shares of common stock outstanding. The company has successfully raised capital through its Capital on Demand™ Sales Agreement, generating net proceeds of approximately $3,194,310 from the sale of shares during the nine months ended September 30, 2024.
Future Outlook
Monopar anticipates that its available funds will support operations into the first half of 2026. The company continues to explore additional funding avenues to support ongoing research and development activities and to facilitate the advancement of its clinical programs.
How Monopar Therapeutics Inc. (MNPR) Works
Company Overview
Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for cancer and rare diseases. As of 2024, the company is advancing its lead product candidates, particularly in the field of radiopharmaceuticals.
Financial Performance
For the three months ended September 30, 2024, Monopar reported the following financial results:
| Metric | 2024 (Q3) | 2023 (Q3) | Variance |
|---|---|---|---|
| Research and Development Expenses | $984,000 | $1,317,000 | $(333,000) |
| General and Administrative Expenses | $591,000 | $749,000 | $(158,000) |
| Total Operating Expenses | $1,575,000 | $2,066,000 | $(491,000) |
| Operating Loss | $(1,575,000) | $(2,066,000) | $491,000 |
| Net Loss | $(1,305,000) | $(1,954,000) | $649,000 |
| Net Loss per Share | $(0.37) | $(0.69) | $0.32 |
For the nine months ended September 30, 2024, the financial summary is as follows:
| Metric | 2024 (YTD) | 2023 (YTD) | Variance |
|---|---|---|---|
| Research and Development Expenses | $3,081,000 | $4,564,000 | $(1,483,000) |
| General and Administrative Expenses | $2,006,000 | $2,355,000 | $(349,000) |
| Total Operating Expenses | $5,087,000 | $6,919,000 | $(1,832,000) |
| Net Loss | $(4,661,000) | $(6,588,000) | $1,927,000 |
| Net Loss per Share | $(1.36) | $(2.43) | $1.07 |
Research and Development Pipeline
Monopar's key product candidates include:
- ALXN-1840: Investigational drug candidate for Wilson disease.
- MNPR-101-Zr: Imaging agent for advanced cancer, currently in Phase 1 clinical trials.
- MNPR-101-Lu: Therapeutic agent for advanced cancer, in Phase 1a clinical trials.
- MNPR-101-Ac: Undergoing late preclinical development for use in advanced cancer therapies.
Cash Flow and Funding
As of September 30, 2024, Monopar reported cash and cash equivalents totaling $6,020,084. The cash flows for the nine months ended September 30, 2024 are summarized below:
| Cash Flow Category | 2024 (YTD) | 2023 (YTD) |
|---|---|---|
| Net Cash Used in Operating Activities | $(4,405,721) | $(6,312,394) |
| Net Cash Provided by Investing Activities | $0 | $1,957,313 |
| Net Cash Provided by Financing Activities | $3,155,428 | $1,692,679 |
| Net Decrease in Cash and Cash Equivalents | $(1,245,996) | $(2,670,841) |
Stockholder's Equity
As of September 30, 2024, Monopar's stockholders' equity was reported as follows:
| Component | Amount |
|---|---|
| Total Stockholders' Equity | $4,946,787 |
| Accumulated Deficit | $(64,867,028) |
| Additional Paid-In Capital | $69,821,281 |
As of October 31, 2024, the total number of shares outstanding was 5,277,796 .
How Monopar Therapeutics Inc. (MNPR) Makes Money
Business Model Overview
Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapies primarily in oncology. The company does not currently generate revenue from product sales, as it is still in the development phase for its drug candidates. Its revenue generation will depend on the successful commercialization of its therapeutic and imaging products, which require regulatory approvals.
Key Drug Candidates
The following table summarizes Monopar's primary drug candidates and their developmental stages:
| Drug Candidate | Indication | Stage | Recent Developments |
|---|---|---|---|
| ALXN-1840 | Wilson Disease | Investigational | Preparation for FDA discussions |
| MNPR-101-Zr | Advanced Cancers | Phase 1 Imaging | Positive early clinical data announced in September 2024 |
| MNPR-101-Lu | Advanced Cancers | Phase 1a | Trial active and open for enrollment as of October 2024 |
| MNPR-101-Ac | Advanced Cancers | Late Preclinical | In preclinical development |
Financial Performance
Monopar has reported significant operating losses as it invests heavily in research and development. Below is a summary of the company's financial performance for the three and nine months ended September 30, 2024:
| Financial Metric | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 |
|---|---|---|---|---|
| Research and Development Expenses | $984,000 | $1,317,000 | $3,081,000 | $4,564,000 |
| General and Administrative Expenses | $591,000 | $749,000 | $2,006,000 | $2,355,000 |
| Total Operating Expenses | $1,575,000 | $2,066,000 | $5,087,000 | $6,919,000 |
| Net Loss | $(1,305,000) | $(1,954,000) | $(4,661,000) | $(6,588,000) |
Capital Raising Activities
Monopar primarily raises capital through sales of its common stock. The following table details the capital raised through its common stock sales:
| Period | Shares Sold | Average Gross Price per Share | Net Proceeds |
|---|---|---|---|
| Nine Months Ended September 30, 2024 | 509,061 | $6.45 | $3,194,310 |
| Nine Months Ended September 30, 2023 | 173,124 | $8.85 | $1,493,205 |
Future Funding Requirements
Monopar anticipates needing substantial additional funding to support its ongoing clinical development and commercialization efforts. As of September 30, 2024, the company reported an accumulated deficit of approximately $64.9 million and expects to continue incurring losses for the foreseeable future.
Cash Flow Analysis
The following table summarizes the cash flows for the nine months ended September 30, 2024 and 2023:
| Cash Flow Component | 2024 | 2023 |
|---|---|---|
| Net Cash Used in Operating Activities | $(4,405,000) | $(6,312,000) |
| Net Cash Provided by Investing Activities | $0 | $1,957,000 |
| Net Cash Provided by Financing Activities | $3,155,000 | $1,692,000 | Net Decrease in Cash and Cash Equivalents | $(1,246,000) | $(2,671,000) |
Conclusion of Financial Position
As of September 30, 2024, Monopar's total stockholders' equity was $4,946,787, with total liabilities and stockholders' equity amounting to $6,069,654. The company's ability to continue operations is contingent upon its capacity to secure additional funding and achieve successful development milestones for its product candidates.
Monopar Therapeutics Inc. (MNPR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Monopar Therapeutics Inc. (MNPR) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Monopar Therapeutics Inc. (MNPR)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Monopar Therapeutics Inc. (MNPR)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.